A 72-Year-Old Female with Lung Cancer

EP. 1: A Patient Case of PD-L1–High Metastatic NSCLC: First-Line Treatment Options

January 27th 2023

Expert oncologist Marina Chiara Garassino, MD, reflects on a patient case of PD-L1–high metastatic NSCLC and outlines first-line treatment options in this setting.

EP. 2: Factors in Selecting First-Line Therapy for PD-L1–High Metastatic NSCLC

ByMarina C. Garassino, MD

January 27th 2023

Comprehensive insight to factors that inform the optimal selection of first-line therapy for patients with PD-L1–high metastatic non–small cell lung cancer.

EP. 3: EMPOWER-Lung1: First-Line Cemiplimab Use in PD-L1–High Advanced NSCLC

ByMarina C. Garassino, MD

January 27th 2023

Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line cemiplimab in managing PD-L1–high metastatic NSCLC.

EP. 4: Potential Role for Chemoimmunotherapy in the 2L Setting of PD-L1–High Advanced NSCLC

ByMarina C. Garassino, MD

January 27th 2023

Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,

EP. 5: PD-L1–High Advanced NSCLC: Future Directions in Care

ByMarina C. Garassino, MD

January 27th 2023

Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.